- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01730469
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Study Overview
Detailed Description
This will be an open-label, non-randomized, multiple-center, sequential group, safety, tolerability, and PK study of a single dose of AT1001 (migalastat HCl, GR181413A) administered orally as a 150 mg dose in fasted healthy control male and female subjects with normal renal function compared to mild, moderate, and severe renally-impaired subjects (classified by level of creatinine clearance [CLcr] as determined by the Cockcroft-Gault formula).
Screening will occur from Day -28 to Day -2. Subjects will check-in to the clinic on Day -1 and receive a single oral dose of 150 mg AT1001 on Day 1. Subjects will be discharged from the clinic on Day 2 (if stable as determined by the Investigator) and return for daily visits on Day 3 through Day 6 for a safety assessment and PK sampling. Subjects will undergo a follow-up visit on Day 7 (+1) and an end of study visit on Day 10 (+1).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Costa Mesa, California, United States, 92626
- GSK Investigational Site
-
-
Florida
-
Miami, Florida, United States, 33169
- GSK Investigational Site
-
Miami, Florida, United States, 33014
- GSK Investigational Site
-
Orlando, Florida, United States, 32809
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria All subjects
- males or females aged 18 to 70 years inclusive (subjects with normal renal function, mild or moderate renal impairment), and 18 to 75 years inclusive (subjects with severe renal impairment)
- body mass index 18.0 to 40.0 kilogram (kg)/square meter (m^2) inclusive
- females who are non-pregnant, non-lactating, or postmenopausal for >=1 year, surgically sterile for >= 90 days, or agree to use approved methods of contraception
- males will be sterile or use approved methods of contraception
- understands and signs informed consent form Healthy subjects with normal renal function
- negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in
- good health with no clinically significant medical history, physical examination, vital signs, or 12-lead ECG
- clinical laboratory tests within the reference range or not clinically significant
- normal renal function (estimated CLcr >90 mL/min) at Screening Subjects with mild, moderate or severe renal impairment
- negative test for selected drugs of abuse (excludes alcohol) at Screening and Check-in or verification of a prescription for a positive test
- renal impairment (estimated CLcr <90 mL/min)
- evidence of stable renal impairment defined as two separate estimated CLcr values within 25%
- clinical laboratory results consistent with their renal condition or of no clinical significance for the study
- abnormal laboratory values must not be clinically significant. Anemia secondary to renal disease is acceptable if hemoglobin is ≥9 g/dL and no clinically significant symptoms. Liver enzymes and bilirubin must be below twice the upper normal level
- subjects with renal impairment must have stable underlying medical conditions < 90 days before study start
- stable medication regimen(s) (no new drug(s) or changed dosage(s) <30 days before study drug)
- in good general health, allowing for concurrent illnesses associated with chronic kidney disease
Exclusion Criteria:
All subjects:
- history of hypersensitivity or allergies to any drug, unless approved by the Investigator and reviewed by Sponsor/Medical Monitor
- participation in a study with receipt of an investigational drug < 5 half-lives or 30 days (whichever is longer) before Check-in
- use of alcohol, grapefruit, or caffeine-containing foods or beverages < 72 hours before Check-in, unless approved by the Investigator and reviewed by the Sponsor/Medical Monitor
- poor peripheral venous access
- whole blood donation < 56 days before dosing or plasma donation < 14 days before dosing
- receipt of blood products < 2 months before Check-in
- history or presence of any clinically significant abnormal ECG
- history of alcoholism or drug addiction < 1 year before Check-in
- positive test for HIV antibody, HBsAg or anti-HCV
- pregnant or breastfeeding
Healthy subjects with normal renal function:
- use of any tobacco- or nicotine-containing products < 6 months before Check-in
- clinically significant (history of or active) cardiac, hepatic, pulmonary, endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or psychiatric disease putting the subject at increased risk or could interfere with study objectives
- screening laboratory values outside normal range and deemed clinically significant by the Investigator
- use of a prescription drug < 14 days of dosing or a non-prescription drug < 7 days before dosing or need of concomitant medication during the study
Subjects with mild, moderate, or severe renal impairment:
- unstable disease (concurrent medical conditions that have changed significantly < 90 days)
- changes in concomitant prescription medications < 30 days before dosing or expected changes during study
- use of new non-prescription medication < 30 days before dosing
- renal transplant
- acute or chronic non-renal condition limiting the subject's ability to complete and/or participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AT1001 150 mg
Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
|
AT1001 150mg is available as a capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with adverse events to assess safety and tolerability
Time Frame: Day 1 to Day 10 (+1)
|
Adverse events will be evaluated from Day 1 to the end of study (Day 10 +1).
|
Day 1 to Day 10 (+1)
|
Clinical laboratory test values to assess safety and tolerability
Time Frame: Day -28 to Day 10 (+1)
|
Clinical laboratory evaluations (hematology, clinical chemistry, urinalysis, Hepatitis A and HIV screen) will be evaluated from screening to the end of the study.
|
Day -28 to Day 10 (+1)
|
Vital signs to assess safety and tolerability
Time Frame: Day -28 to Day 10 (+1)
|
Vital signs (oral temperature, respiratory rate, and seated blood pressure) will be performed from screening to the end of the study.
|
Day -28 to Day 10 (+1)
|
Physician examination to assess safety and tolerability
Time Frame: Day -28 to Day 10 (+1)
|
Physical examination (general appearance, skin, thorax/lungs, cardiovascular and abdomen) will be performed from screening to the end of the study.
|
Day -28 to Day 10 (+1)
|
Measure of ECG to assess safety and tolerability
Time Frame: Day -28 to Day 10 (+1)
|
Electrocardiogram (ECG) measures the electrical activity of the heart and the hearts' rhythm.
All subjects will undergo ECG testing.
|
Day -28 to Day 10 (+1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed concentration (Cmax) of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the resultant maximum plasma concentration (Cmax) will be measured in subjects with impaired renal function and normal renal function.
|
Day 1 to Day 6
|
Time to achieve maximum concentration (Tmax) of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and time to maximum concentration (tmax) will be measured in subjects with impaired renal function and normal renal function.
|
Day 1 to Day 6
|
Apparent terminal elimination half life (t1/2 ) of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and and apparent terminal elimination half-life (t1/2) will be measured in subjects with impaired renal function and normal renal function.
|
Day 1 to Day 6
|
Area under the concentration-time curve from time zero to the last measurable concentration (AUC 0-t ) of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and AUC 0-t will be measured in subjects with impaired renal function and normal renal function
|
Day 1 to Day 6
|
Area under the concentration-time curve extrapolated to infinity (AUC 0-inf) of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and AUC 0-inf will be measured in subjects with impaired renal function and normal renal function
|
Day 1 to Day 6
|
Apparent terminal elimination rate constant for AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the apparent terminal elimination rate constant will be measured in subjects with impaired renal function and normal renal function
|
Day 1 to Day 6
|
Oral clearance of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the oral clearance will be measured in subjects with impaired renal function and normal renal function
|
Day 1 to Day 6
|
Oral volume of distribution of AT1001
Time Frame: Day 1 to Day 6
|
Blood samples will be collected at predose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15, 24, 48, 72, 96, and 120 hours post-dose and the oral volume of distribution will be measured in subjects with impaired renal function and normal renal function
|
Day 1 to Day 6
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Kidney Diseases
- Urologic Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Renal Insufficiency
- Fabry Disease
Other Study ID Numbers
- 116431
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Wuerzburg University HospitalTakedaEnrolling by invitationLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
University Hospital, RouenUnknownAnderson-Fabry DiseaseFrance
-
Sangamo TherapeuticsEnrolling by invitationFabry Disease | Fabry Disease, Cardiac VariantUnited States, Australia, United Kingdom
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
-
Wolfson Medical CenterUnknownFabry Disease in the Young StrokeIsrael
Clinical Trials on AT1001 150 mg
-
Amicus TherapeuticsRecruitingFabry DiseaseSpain, United States, Japan, Australia, France, Portugal
-
Amicus TherapeuticsCompletedFabry DiseaseUnited Kingdom, United States
-
Amicus TherapeuticsActive, not recruitingFabry DiseaseUnited States, United Kingdom
-
Amicus TherapeuticsCompletedOpen-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseFabry DiseaseUnited States, Austria, United Kingdom, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Egypt, France, Italy, Japan, Spain, Turkey
-
9 Meters Biopharma, Inc.CompletedCeliac DiseaseCanada, United States
-
Massachusetts General HospitalCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Georgetown UniversityUnknown
-
Novartis PharmaceuticalsCompletedHypertensionUnited States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
-
Samsung Medical CenterCompletedStomach NeoplasmsKorea, Republic of
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-type PsoriasisUnited States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada